Q2 Earnings Forecast for TOI Issued By B. Riley

The Oncology Institute, Inc. (NASDAQ:TOI) – Research analysts at B. Riley issued their Q2 2025 earnings estimates for shares of Oncology Institute in a report released on Tuesday, July 15th. B. Riley analyst Y. Zhi anticipates that the company will post earnings of ($0.13) per share for the quarter. B. Riley has a “Strong-Buy” rating on the stock. B. Riley also issued estimates for Oncology Institute’s Q3 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.55) EPS and FY2025 earnings at ($0.55) EPS.

Separately, BTIG Research started coverage on Oncology Institute in a research report on Thursday, May 15th. They issued a “buy” rating and a $7.00 price target for the company.

Oncology Institute Price Performance

Shares of NASDAQ TOI opened at $3.50 on Friday. The company has a 50 day simple moving average of $2.74 and a two-hundred day simple moving average of $1.75. Oncology Institute has a fifty-two week low of $0.13 and a fifty-two week high of $3.78. The company has a market capitalization of $312.31 million, a price-to-earnings ratio of -5.00 and a beta of 0.02. The company has a debt-to-equity ratio of 14.58, a quick ratio of 1.59 and a current ratio of 1.79.

Oncology Institute (NASDAQ:TOI) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.18) earnings per share (EPS) for the quarter. Oncology Institute had a negative return on equity of 445.02% and a negative net margin of 15.38%. The firm had revenue of $104.41 million during the quarter.

Hedge Funds Weigh In On Oncology Institute

A number of hedge funds have recently modified their holdings of the company. Josh Arnold Investment Consultant LLC bought a new position in Oncology Institute in the 1st quarter worth approximately $2,267,000. Renaissance Technologies LLC lifted its holdings in shares of Oncology Institute by 7.1% in the fourth quarter. Renaissance Technologies LLC now owns 182,000 shares of the company’s stock worth $56,000 after buying an additional 12,000 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Oncology Institute during the fourth quarter worth $41,000. Jane Street Group LLC grew its stake in Oncology Institute by 613.6% during the fourth quarter. Jane Street Group LLC now owns 127,659 shares of the company’s stock valued at $39,000 after acquiring an additional 109,769 shares in the last quarter. Finally, Goldman Sachs Group Inc. bought a new stake in Oncology Institute in the 1st quarter valued at $131,000. 36.86% of the stock is currently owned by institutional investors.

Insider Activity

In other Oncology Institute news, Director Growth I. L.P. M33 sold 1,796,468 shares of the stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $2.71, for a total value of $4,868,428.28. Following the transaction, the director directly owned 14,624,233 shares in the company, valued at approximately $39,631,671.43. This trade represents a 10.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Brad Hively sold 1,976,137 shares of the company’s stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $2.87, for a total value of $5,671,513.19. Following the completion of the sale, the director owned 603,501 shares of the company’s stock, valued at $1,732,047.87. This trade represents a 76.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 4,726,137 shares of company stock worth $13,379,013 over the last three months. Insiders own 8.50% of the company’s stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.